S&P 500 Achieves “Perfect Week” Despite Pockets of Volatility & Macroeconomic Crosscurrents – ( $DNUT $EPRX $GOVX $MCD $META $MODD $NVDA $PLTR $RIO $SER $SPY $SMMT $TDOC Rise!)

By John F. Heerdink, Jr.

Wall Street’s upward march persisted despite pockets of volatility and macroeconomic crosscurrents. With record equity closes, firmer retail sales, and large cap technology squarely in focus, investors enter the heart of earnings season bracing for fresh signals on growth, inflation, and central bank direction in the summer ahead. Yes, indeed in a week marked by record equity highs, resilient consumer data, and continued trade policy tensions, U.S. markets extended their rally, though with flashes of volatility in tech and electric vehicles.

Index Performance

The S&P 500 set a new record, rising 1.5% for the week and closing at 6,388.64, achieving the rare distinction of notching a “perfect week” of consecutive record highs from Monday to Friday.

The Nasdaq Composite similarly advanced, gaining 1% to a new record of 21,108.32, buoyed by optimism surrounding large cap tech earnings and AI momentum. The Dow Jones Industrial Average outperformed its recent trend, climbing 1.3% to 44,901.92 as investors rotated into cyclical and value names following profit-taking in previous weeks.

Meanwhile, the Russell 2000 continued its July resurgence, up nearly 9% month-to-date, as small-cap stocks found favor on hopes for upcoming rate cuts and improving economic sentiment.

Macroeconomic Reports

Economic data remained mixed but broadly constructive:

Inflation: Consumer Price Index data remained sticky, with higher readings in categories most exposed to tariffs. Producer price inflation, however, showed a more modest trend, easing concerns over a re-acceleration in input costs.

Retail Sales: Retail sales surprised to the upside, once again demonstrating the durability of the U.S. consumer.

Labor Market: Weekly jobless claims declined for the fifth consecutive week, signaling ongoing strength in employment and providing a stable backdrop for spending and investment.

Corporate News Highlights

NVIDIA (NVDA, $173.50, +.63% over the last 5-days): Nvidia shares rebounded, touching new highs on Friday amid anticipation of upcoming quarterly results. Although the stock lost 3.3% earlier in the week as early July momentum faded, investor enthusiasm for its AI leadership and impending earnings kept sentiment strong. Analysts affirmed a consensus “Strong Buy” outlook for the stock, with robust revenue and earnings growth projections heading into its August report.

Tesla (TSLA, $316.06, -4.12% over the last 5-days): Tesla endured a notably turbulent week, with shares plunging as much as 10% Thursday following disappointing quarterly sales and CEO Elon Musk’s warning of “a few rough quarters ahead.” Tariff headwinds and dwindling EV incentives in the U.S. compounded the pressure. Tesla reported its most significant sales decline in over a decade, reducing future delivery projections and pointing to broader challenges for the EV sector.

Meta Platforms (META, $712.68, +1.19% over the last 5-days): Meta remained in the spotlight with investors’ eyes on its forthcoming earnings next week. The stock traded largely in line with peers, amid ongoing optimism about large-scale data center investments and AI growth.

McDonald’s (MCD, $298.47, +.47% over the last 5-days): No major news; stock followed sector trends without notable headlines this week.

Rio Tinto Group (RIO, $63.10, +4.23% over the last 5-days): No significant announcements impacting U.S. trading; the stock tracked broader commodity movements.

Palantir Technologies (PLTR, $158.80, +3.44% over the last 5-days): The company remained quiet on the news front, but shares benefitted tangentially from interest in AI and government tech contracts.

Mergers, Acquisitions, and IPOs

The S&P 500 saw only modest activity on the M&A front, but market headlines were made as Paramount Global’s merger with Skydance Media received regulatory approval, inking an $8.4 billion deal. This move, although outside the S&P 500, underscores the ongoing media consolidation trend.

IPO activity on the NYSE and Nasdaq remained muted, with no high-profile offerings announced or priced this week as summer seasonality and valuation apprehension persisted.

Tariffs and Trade Policy

Trade policy remained a driving force across markets:

The White House stood firm on its August 1 tariff deadline, confirming that affected nations will face new duties unless progress is demonstrated. U.S. officials repeated warnings of possible 15%-30% tariffs on European goods, adding to ongoing friction over Chinese tariffs that weighed on EV and tech names.

Reports indicated U.S. consumers have not yet significantly pulled back on spending due to tariffs, though inflation pressures in exposed categories are noticeable.

Yield Curve, Interest Rates, and Fed Policy

Treasury yields ended the week mixed. The short end gained, while long-dated yields retreated slightly after early week spikes tied to speculation about Fed independence and potential leadership changes.

The probability of a July rate cut is low (5%), but markets are pricing nearly a 60% likelihood of a cut in September, reflecting hope for central bank support as inflation starts to wane.

No FOMC meeting was held this week; the next decision is expected in August, with policymakers closely monitoring tariff fallout and evolving inflation data.

Commodities & Cryptocurrency

Gold and Silver: Gold dropped 1.86% over the last 5-days closing at $3,338.50/oz. Silver closed at $38.325/oz. down 1.98% over the last 5-days.

Crude Oil prices fell during the week, retracing on fading geopolitical tensions and stable global output closing at $65.07/bbl down 3.17% over the last 5-days..

Bitcoin and Crypto Stocks: Bitcoin

remained volatile, trading higher for the week in tandem with tech and risk assets and closed at $115,450 after reaching $120,330. Crypto-related stocks advanced modestly, mirroring the rebound in major U.S. indices.

Meme Stock Frenzy: Krispy Kreme and Other Big Movers

This week, the equity markets weren’t just marked by record indexes—they were animated by a dramatic meme-stock resurgence that echoed the trading frenzies of 2021. Leading this cavalcade was Krispy Kreme (DNUT), which experienced wild swings as retail traders, galvanized by social media, poured into heavily shorted stocks. On Wednesday, Krispy Kreme surged as much as 34% premarket and ultimately closed up 4.5% on the day**, while intraweek volatility saw its shares oscillating by nearly 39% intraday before settling back as the rally faded.

Analysts attribute DNUT’s sharp moves—up more than 31% over the past two weeks—to a potent mix of high short interest, meme-fueled buying, and spillover optimism from tech and crypto sectors. Despite analyst price target downgrades, the momentum among retail traders overpowered typical fundamentals during the chase for quick profits. On trading forums such as Reddit’s WallStreetBets, Krispy Kreme became one of the week’s most-cited tickers, joining other so-called “DORK” names—Opendoor Technologies (OPEN), Kohl’s (KSS), GoPro (GPRO)—that took turns soaring as part of the week’s speculative wave.

Analysts note that this frenzy was largely driven by retail investors emboldened by recent market highs and robust risk appetite, as evidenced by speculative trading indicators reaching levels not seen since 2021. While these bursts of volatility—often untethered from company fundamentals—brought big rewards for some, warnings abounded about the sustainability of such rallies and the risks of sharp reversals once social buying power abates.

The meme mania, while providing spark and headlines, ultimately settled down by week’s end as reality set in and broader markets resumed their methodical upward march. Still, the sharp movements in Krispy Kreme and other “meme” tickers were a significant subplot for Wall Street as July closed out.

Vista Partners Watchlist Highlights & Updates

Eupraxia Pharmaceuticals (EPRX, $5.49, +3.82% one the last 5-days) is clinical-stage biotechnology firm headquartered in Victoria, Canada, has quietly become one of the more intriguing stories on both sides of the border in 2025. The company’s shares now trade under the ticker EPRX on both the Nasdaq and the Toronto Stock Exchange, following its U.S. market debut in April 2024. This dual listing has broadened its investor base at a time when the company’s clinical and financial narrative is gaining momentum. All covering analysts currently rate the stock as a “Buy” or better, with not a single “Hold” or “Sell” recommendation in sight. In a sector defined by binary outcomes and frequent disappointment, such unanimity is striking. Overall, analysts cite Eupraxia’s strong clinical pipeline and revenue growth potential as key drivers behind their bullish outlook. Today (July 24), Cantor Fitzgerald initiated coverage on Eurpaxia with an Overweight rating and a $11 Price Target. Their report is titled “Set It and Forget It” Approach to EOE & Beyond.” Here are the other analysts that cover Eupraxia currently:

HC Wainwright: Initiated Covrage on EPRX with a “Strong Buy” on June 26, 2025.
Canaccord Genuity: Initiated coverage with a “Speculative Buy” rating in June 2025.
Raymond James Ltd.: Maintains a “Strong Buy” rating as of June 2025, with a history of upgrades from “Outperform” to “Strong Buy” over the past year.
Research Capital Corporation: Maintains a “Buy” rating, consistently reaffirming its positive stance throughout 2024 and 2025.

Eupraxia announced on July 8 that the first patient dosed in their Phase 2b randomized, placebo-controlled portion of the RESOLVE clinical trial evaluating EP-104GI, an investigational treatment for eosinophilic esophagitis (“EoE”). EP-104GI is injected directly into the affected tissues of the esophagus to reduce inflammation with stable, localized, and long-duration drug delivery, while minimizing unwanted systemic adverse events and side effects often associated with steroid-based therapies. The Phase 2b portion of the RESOLVE study will enroll a minimum of 60 participants randomized in a 1:1:1 ratio to receive one of two doses of EP-104GI or placebo. After six months, eligible patients initially dosed with placebo may elect to receive EP-104GI. The primary objective is to assess the efficacy of EP-104GI in improving tissue health, as measured by the Eosinophilic Esophagitis Histology Scoring System (“EoEHSS”). Secondary and exploratory objectives include evaluating symptomatic improvement through patient-reported outcomes — Straumann Dysphagia Index score (SDI) and Dysphagia Symptom Questionnaire (DSQ), endoscopic and histologic changes (including Peak Eosinophil Count, “PEC”), pharmacokinetics, safety, and tolerability of the selected dose regimens. Up to 25 sites globally are expected to participate in the trial.The Phase 2b portion of the study employs an innovative adaptive design to select the doses of EP-104GI that are administered to patients. The first active dose selection was based on available data from cohorts 1 to 8 of the Phase 2a portion of the study. Based on the previously reported safety, pharmacokinetic, and efficacy data from cohorts 1 to 6, and additional one month data from cohorts 7 and 8, the 120 mg dose (20 injections of 6 mg per site) from cohort 8 was selected for the first treatment arm in the dose optimization phase. A second dose will be selected for evaluation after enrollment in the first arm is complete, based on additional long-term data from the Phase 2a portion of the study. James Helliwell, CEO of Eupraxia Pharmaceuticals stated, “Entering into the Phase 2b stage of the RESOLVE trial is a significant event for Eupraxia. This is an important step for us before proceeding towards the pivotal trials necessary for submitting an application for regulatory approval. We are optimistic that EP-104GI has the potential to significantly advance the standard of care and offer a meaningful new treatment paradigm for patients living with EoE.”

Tribe Public hosted a CEO Presentation and Q&A Webinar Event on Wednesday, May 14th with James A. Helliwell, Director and CEO of Eupraxia Pharmaceuticals (NASDAQ: EPRX). The event is titled “Hard To Swallow: An Underdiagnosed Condition Rising To Surface (EOE).” You may view it now at https://youtu.be/tCtY_27EJG4?si=0PJIp-oyGDEpzxzR

Summit Therapeutics Inc. (NASDAQ: SMMT, $28.67, +9.43% over the last 5-days) is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.

Summit announced (May 30) topline results from the Phase III clinical trial, HARMONi, the first global Phase III study evaluating ivonescimab, successfully met the progression-free survival (PFS) primary endpoint and showed a positive trend in the other primary endpoint, overall survival (OS). HARMONi is a multiregional, double-blinded, placebo-controlled, Phase III study sponsored by Summit evaluating ivonescimab plus platinum-doublet chemotherapy compared to placebo plus platinum-doublet chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with a 3rd generation EGFR tyrosine kinase inhibitor (TKI). This is a clinical setting with a patient population where PD-1 monoclonal antibodies have previously been unsuccessful in Phase III global clinical trials in showing either a PFS or OS benefit.

Modular Medical, Inc. (NASDAQ: MODD, $.7140, +3.48% over the last 5-days), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Their mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond “superusers” and providing “diabetes care for the rest of us.” Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.

On June 16, Modular Medical announced its participation in the American Diabetes Association (“ADA”) 85th Scientific Sessions, taking place June 20-23, 2025, at the McCormick Place Convention Center in Chicago, Illinois. The Company will feature a poster, number 783-P, titled “Elucidating the potential benefit of pump-delivered subcutaneous GLP-1R agonist: an exploratory study in the diet-induced obese mouse,” to be presented by David Maggs, MD, FRCP during the General Poster Session on Sunday, June 22, 2025, from 12:30pm to 1:30pm in the Poster Hall. The presentation will highlight data from an exploratory study evaluating the effects of pump-delivery of a short-acting GLP-1RA on weight, food intake, and glucose tolerance in a diet-induced obese (“DIO”) mouse.”We are excited to share our findings from this novel study in the DIO mouse comparing the pump delivery of exenatide to intermittent dosing of semaglutide,” said Jeb Besser, CEO of Modular Medical. “Given the high rate of gastrointestinal tolerability challenges and resultant discontinuation that is characteristic of GLP-1 therapy, we believe that a personalized approach to GLP-1 titration and dosing, including a mealtime bolus option, would give patients an opportunity to reach their treatment goals, while experiencing easier therapy initiation and a more tolerable maintenance regimen.”

After the close May 28, Modular Medical announced the appointment of Jeff Goldberg to its Board of Directors. Mr. Goldberg brings decades of experience in health care, life sciences, and medical device leadership, including development of generic insulin. Mr. Goldberg began his work in medical technology alongside pioneering medical entrepreneur, and founder of MiniMed, Alfred E. Mann. Mr. Goldberg currently serves as Chairman of Lannett Company, Inc., a generic pharmaceutical manufacturer where he has helped execute a post-restructuring turnaround. During his tenure, Lannett has made significant strides in launching a generic insulin product – progress that aligns closely with Modular Medical’s commitment to innovation and affordability in diabetes care. In addition to his work at Lannett, Mr. Goldberg previously served as President and CEO within Alfred E. Mann’s incubator, IncuMed, where he oversaw multiple portfolio companies focused on drug-device combination products, including an insulin patch-pump program. His tenure with Mr. Mann’s enterprises included pivotal roles in regulatory strategy, operations turnaround, and successful exits, underscoring his ability to guide early-stage technologies to commercial viability. Mr. Goldberg also serves on the boards of several health-care and consumer-focused companies, including ATI Physical Therapy, Cano Health, and Eating Recovery Centers. He holds a JD from UCLA School of Law and an AB from Harvard College. Mr. Goldberg stated, “Modular Medical is advancing a truly disruptive approach to insulin delivery. I’m excited to join the board and contribute to the Company’s journey toward simplifying treatment for people living with diabetes, particularly as the industry shifts toward more accessible and patient-friendly solutions.”

Jeb Besser, CEO of Modular Medical, presented on May 29 at Tribe Public’s Webinar Presentation and Q&A Event titled“Making Diabetes Management Simpler: The New Era of Insulin Therapy.”You may view the event video now at the Tribe Public YouTube Channel.

Shares of ADT Inc. (ADT, $8.44, -.12% over the last 5-days) is a leading provider of monitored security and automation solutions for residential and small business customers in the United States and Canada.

ADT released Q1, 2025 results on Thursday, April 24 and highlighted the following: Continued strong financial results with record recurring monthly revenue and customer retention, GAAP operating cash flows up 28%, Adjusted Free Cash Flow including interest rate swaps up 105%, Returned $445 million to shareholders through share repurchases and dividends, and that they are on track to achieve full year 2025 guidance metrics.

On April 30, ADT in collaboration with Yale and the Z-Wave Alliance, announced the launch of the Yale Assure Lock 2 Touch with Z-Wave for ADT+. The Z-Wave 800 Series smart lock is the only one on the market with fingerprint control and the first smart lock to leverage the newly introduced Z-Wave User Credential Command Class. This industry-first innovation allows users to unlock and disarm their ADT+ security system using just their fingerprint.

On Jan. 22, ADT announced the appointment of Thomas Gartland to the Company’s Board of Directors as an additional independent director. In conjunction with his appointment, Gartland will join the Board’s Audit Committee. Gartland is chairman and chief executive officer of Montway Auto Transport, a privately held auto transport company, and has held this position since 2023. Prior to Montway, Gartland served as executive chairman of Scan Global Logistics and as president, North America, for Avis Budget Group. Gartland serves on the boards of Xenia Hotels & Resorts, Inc. and ABM.

GeoVax Labs, Inc. (Nasdaq: GOVX, $.79, +3.27% over the last 5-days) is a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases.

On July 24, GeoVax announced a strategic shift in its Gedeptin(R) clinical development program, with a new emphasis on evaluating Gedeptin as a neoadjuvant therapy in combination with pembrolizumab for patients with primary, resectable head and neck squamous cell carcinoma (HNSCC). The revised strategy follows the landmark results of the KEYNOTE-689 Phase 3 trial, published in the New England Journal of Medicine on June 18, 2025, which demonstrated a significant improvement in event-free survival (EFS) with the addition of perioperative pembrolizumab in resectable, locally advanced HNSCC patients. These data represent the first validated use of PD-1 inhibition in curative-intent HNSCC and have catalyzed a major shift in treatment paradigms toward neoadjuvant immunotherapy.

On July, 21, GeoVax reinforced the strategic and commercial significance of the recent positive Scientific Advice (SA) received from the European Medicines Agency (EMA) for its GEO-MVA vaccine targeting Mpox and smallpox. The EMA’s feedback indicated that a single Phase 3 immuno-bridging trial, bypassing the need for Phase 1 and 2 studies, may be sufficient to support a Marketing Authorization Application (MAA) under the EU’s centralized procedure. The ability to proceed without Phase 1 and 2 clinical trials substantially reduces development risk and timelines, positioning GeoVax to achieve product commercialization and revenue generation significantly earlier than previously anticipated. Immuno-bridging studies allow for vaccine approval by the immune response elicited by a candidate vaccine comparable to that of an already approved vaccine. This approach, when accepted by regulatory authorities, can reduce the need for large-scale efficacy trials, thereby reducing development time while maintaining regulatory standards for safety and immunogenicity. “This EMA guidance is more than a regulatory milestone; it represents a potential commercial inflection point,” said David Dodd, Chairman and CEO of GeoVax. “We now have a clear, expedited path to commercialization in one of the world’s largest vaccine markets. With the Phase 3 trial in operational preparation, we are entering a potential revenue acceleration phase supported by growing global demand, regulatory momentum, and our progressing advanced MVA manufacturing platform.”

On July 16, GeoVax issued a statement underscoring the increasing urgency of expanding global Mpox vaccine access, as recent data from the Airfinity July 2025 Mpox Report highlight significant new outbreaks and rising global transmission of Clade I and Clade II Mpox.

On July 3, GeoVax emphasized the urgent need for innovation in COVID-19 vaccination as the NB.1.8.1 variant – commonly known as “Nimbus” – spreads rapidly across the globe. Nimbus, a highly transmissible Omicron subvariant classified by the World Health Organization as a “Variant Under Monitoring,” is now dominant in multiple U.S. states and surging across Europe and Asia. Though not more severe, its rapid spread and potential for immune escape reflect an increasingly clear reality: COVID-19 is not going away, and it will continue to evolve.

Indaptus Therapeutics, Inc. (Nasdaq: INDP, $9.92) is a company with the ability to harness both the body’s innate and adaptive immune responses, believes that they are uniquely positioned to revolutionize the treatment of cancer and certain infectious diseases.

On July 1, Indaptus announced the additional sale of approximately $3.4 million in aggregate principal amount of convertible promissory notes and accompanying warrants. Together with a prior sale of $2.3 million of convertible promissory notes and accompanying warrants, the Company raised an aggregate of $5.7 million in gross proceeds in this offering.

On June 2, Indaptus announced that the first patient has been dosed in the expansion arm of its Phase 1b/2 clinical trial evaluating Decoy20 in combination with BeOne’s (formerly known as Beigene) PD-1 checkpoint inhibitor, tislelizumab. This newly activated arm of the trial will assess safety, dose optimization, and early signs of anti-tumor activity in patients with advanced solid tumors, previously treated with a checkpoint inhibitor or with tumors typically unresponsive to a checkpoint inhibitor. Jeffrey Meckler, Indaptus’ CEO commented, “This is an important milestone in our clinical development. We have long believed the Decoy platform has the potential to be a game-changing approach to treating solid tumors. Preclinical data consistently demonstrated that Decoy20 works synergistically with a checkpoint inhibitor. Now, for the first time, we are testing this combination in patients. Checkpoint inhibitors, like tislelizumab, have been one of the biggest breakthroughs in cancer therapy and have significantly improved outcomes in a variety of cancers. However, most patients still do not benefit. We believe the combination of Decoy20 plus a PD-1 inhibitor, such as tislelizumab, could enhance immune responses, potentially helping patients who have not responded or have tumors that classically do not respond to checkpoint inhibitor therapy.”

Teladoc Health (TDOC, $8.20, +1.86% over the last 5-days) is the world leader in virtual care. Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Teladoc Health leverages more than two decades of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com. Teladoc will release second quarter 2025 results on Tuesday, July 29, 2025, after the market closes.

Serina Therapeutics, Inc. (NYSE American: SER, $5.40, +.75% over last 5-days), a clinical-stage biotechnology company, today announced that its Board of Directors has established November 7, 2025, as the date of its 2025 annual meeting of stockholders (the “Annual Meeting”). The time and location of the Annual Meeting will be set forth in the Serina’s definitive proxy statement for the Annual Meeting to be filed with the Securities and Exchange Commission (the “SEC”). Because the date of the Annual Meeting represents a change of more than 30 days from the anniversary of Serina’s 2024 annual meeting of stockholders, the deadline for stockholder proposals to be submitted pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), for inclusion in Serina’ proxy materials for the Annual Meeting will be 5:00 p.m. (Central Time) on Friday, August 15, 2025, which Serina’s Board of Directors has determined to be a reasonable period of time before Serina expects to begin to print and send its proxy materials for the Annual Meeting. Stockholder proposals submitted in accordance with Rule 14a-8 of the Exchange Act must also comply with the remaining requirements of Rule 14a-8 in order to be included in the proxy materials for the Annual Meeting. Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit https://serinatherapeutics.com.

Quote of the Day

“Hope is but the dream of those who wake.” – Matthew Prior

Sources

1] S&P 500, Nasdaq close at records; Deckers soars on UGG demand https://www.reuters.com/business/sp-500-nasdaq-close-records-deckers-soars-ugg-demand-2025-07-25/

[2] How major US stock indexes fared Friday, 7/25/2025 https://www.timesunion.com/business/article/how-major-us-stock-indexes-fared-friday-7-25-2025-20786716.php

[3] How major US stock indexes fared Friday, 7/25/2025 https://www.nhregister.com/business/article/how-major-us-stock-indexes-fared-friday-7-25-2025-20786716.php

[4] How major US stock indexes fared Friday, 7/25/2025 – Seattle PI https://www.seattlepi.com/business/article/how-major-us-stock-indexes-fared-friday-7-25-2025-20786716.php

[5] Small-Cap ETFs Rally in July: Will the Momentum Continue? https://www.nasdaq.com/articles/small-cap-etfs-rally-july-will-momentum-continue

[6] Market Commentary: Week of July 21, 2025 – SWBC Blogs https://blog.swbc.com/investmenthub/market-commentary-week-of-july-21-2025

[7] Reports for the week | Al Maulini, CFP®, CPM®, CEPA® – LinkedIn https://www.linkedin.com/posts/almaulini_reports-for-the-week-major-economic-reports-activity-7353159753914564609-yoEG

[8] NVIDIA (NASDAQ: NVDA) Price Prediction and Forecast 2025-2030 for July 22 https://247wallst.com/forecasts/2025/07/22/nvidia-nvda-price-prediction-and-forecast/

[9] Nvidia Scores New Highs As Amazon, Meta, Apple Earnings Loom – Is Nvidia Stock A Buy Now? https://www.investors.com/research/nvidia-nvda-stock-buy-now-july-2025/

[10] Tesla shares fall amid delays, distractions and fading EV dominance https://www.reuters.com/business/autos-transportation/tesla-shares-fall-amid-delays-distractions-fading-ev-dominance-2025-07-24/

[11] Tesla stock plunges as Elon Musk warns company may face ‘a few rough quarters’ ahead https://nypost.com/2025/07/24/business/tesla-stock-plunges-as-elon-musk-admits-a-few-rough-quarters-could-be-ahead/

[12] Stock market news for July 21, 2025 – CNBC https://www.cnbc.com/2025/07/20/stock-market-today-live-updates.html

[13] [PDF] Performance Insights US – LSEG https://www.lseg.com/content/dam/ftse-russell/en_us/documents/market-insights/performance/monthly-performance-report-us-july-2025.pdf

[14] Perplexity Finance – Quotes, Forecasts, News, Charts, and More https://www.perplexity.ai/finance

[15] Dow Jones Chart By 2025 | StatMuse Money https://www.statmuse.com/money/ask/dow-jones-chart-by-2025

[16] Stock Market Today: S&P 500 Wraps Week With Fifth Straight Record https://www.wsj.com/livecoverage/stock-market-today-dow-sp500-nasdaq-07-25-2025

[17] Dow Jones Today: S&P 500, Nasdaq Close Out Strong Week at … https://www.investopedia.com/dow-jones-today-07252025-11779019

[18] Weekly Market Recap — Manulife John Hancock Investments https://www.jhinvestments.com/weekly-market-recap

[19] Stock Market News for Jul 25, 2025 https://www.nasdaq.com/articles/stock-market-news-jul-25-2025

[20] Week Ahead Economic Preview: Week of 21 July 2025 | S&P Global https://www.spglobal.com/marketintelligence/en/mi/research-analysis/week-ahead-economic-preview-week-of-21-july-2025.html

[21] Earnings Scheduled For July 25, 2025 https://www.nasdaq.com/articles/earnings-scheduled-july-25-2025

Investing & Inspiration

“We cannot live only for ourselves. A thousand fibers connect us with our fellow men.” – Herman Melville

Post View Count : 501

Stay Informed. Stay Competitive.

Vista Partners offers an exclusive newsletter and content with daily, weekly, monthly and quarterly investing ideas, strategies, and marketing insights.

We value your privacy and will never share your information.